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INTRODUCTION
Despite continuous evolution of the antimicrobial 
armamentarium, until recently mortality due to com-
munity-acquired pneumonia (CAP) tends to remain in 
considerably high levels1,2. Implementation of CAP 
guidelines has been consistently shown to result in 
improvements in clinically relevant outcomes and 
mortality2-6. Moreover, the Infectious Diseases Soci-
ety of America and the American Thoracic Society 
(IDSA/ATS) guidelines for CAP strongly recommend 
the compliance with locally adapted guidelines2. 
Two important aspects in the implementation of 
such guidelines are the selection of patients that re-
quire hospitalization and the appropriate choice of 
initial empirical treatment. As for the detection of 
patients who need to be admitted, several algorithms 
assessing the severity of the pneumonia and predict-
ing the risk of death have been developed2,7-10. CURB-
65 index is a simple and attractive to routine clinical 
practice prognostic rule that was proposed by Lim et 
al7 in response to the previously introduced and more 
complex Pneumonia Severity Index (PSI)11. CURB-65 
consists of five easily measurable parameters (Confu-
sion, Urea, Respiratory rate, systolic and/or diastolic 
Blood pressure and age over 65 years). According to 
CURB-65 score, patients with a score of 0-1, having 
very low mortality risk, can be treated safely as outpa-
tients2,7,12. Although CURB-65, as well as some other 
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severity assessing rules, has been repeatedly proposed 
by numerous guidelines2,13 as a valuable tool for the 
identification of low risk patients, multiple studies 
have demonstrated that 30-60% of such low-risk pa-
tients with CAP are admitted in hospitals, increasing 
tremendously the cost of therapy2,6,14-18. 
Several studies have provided convincing evi-
dence that although guidelines-compliant treatment 
results in improved survival and reduced health-care 
costs, concordance with guidelines remains subopti-
mal19-22. The above conclusion applies also to the case 
of Greece23,24 where in addition, high-level macrolide-
resistant S. pneumoniae is reported25,26. Consequently, 
Greek national guidelines advise the use of respiratory 
fluoroquinolones or the combination of a beta-lactam 
with adequate anti-pneumococcal potency plus a mac-
rolide for the treatment of CAP including both in- and 
outpatients27.
The primary aim of this study was to assess the 
compliance of Greek physicians working in public 
hospitals to the Greek National Guidelines concern-
ing the use of CURB-65 index for the selection of pa-
tients who require hospitalization. In addition we in-
vestigated whether the empirical antibiotic treatment 
administered to the patients was appropriately chosen. 
PATIENTS AND METHODS
Patients
This is an observational prospective multi-center study 
conducted at three General Hospitals in Thessaloniki, 
a city with a population greater than 1.000.000 inhab-
itants, in Northern Greece. We analyzed the data of 
patients hospitalized due to CAP in two departments 
of pulmonary medicine in «G. Papanikolaou» General 
Hospital and two departments of internal medicine in 
«Papageorgiou» and «Hippokration» General Hospi-
tals. Recording was performed from January 2011 to 
January 2013, one week per month by the same group 
of physicians, who were independent of the physi-
cians deciding the patients’ admission to the hospital 
and antimicrobial treatment.
Patients eligible for the study were adults admitted 
through the ED with a new infiltrate or consolidation 
on their chest-radiograph, along with at least one of 
the following signs or symptoms of lower respiratory 
tract infection: acute illness with cough, fever > 3 
days, dyspnea, new focal chest signs. Exclusion crite-
ria were: age < 18 years, hospital-acquired pneumonia 
(development of symptoms > 48 h after admission or 
discharge from an acute care facility < 2 weeks prior 
to admission), healthcare associated pneumonia, im-
munosuppression and previously known bronchiec-
tasis. The study design was approved by the Ethics 
Committees of the participating hospitals and written 
informed consent was obtained from all study partici-
pants. 
For each patient CURB-65 was assessed within 24 
hours of admission based on data recorded at the time 
of admission. As previously described7, CURB-65 
consists of five easily measurable parameters and the 
final score is build after charging one point for each of 
the following: Confusion, serum Urea > 7 mmol/l or 
42 mg/dl, Respiratory rate ≥ 30/ min, systolic Blood 
pressure < 90 mmHg and/or diastolic Blood pressure 
< 60 mmHg and finally, age ≥ 65 years. 
In addition aggravating factors not included in 
CURB-65 were assessed. The following parameters 
were recorded: age, gender, prior antimicrobial ther-
apy, blood gas analysis (pH, pO2, pCO2, HCO3), oxy-
gen saturation, supplementary oxygen administration, 
presence of pleural fluid, number of pulmonary lobes 
infected, antimicrobial therapy upon admission and 
outcome at hospital discharge.
Appropriateness of empirical treatment
In order to evaluate the appropriateness of empirical 
treatment administered upon admission, we assessed 
empirical antibiotic treatment agreement with Greek 
guidelines for CAP. According to the Greek National 
Guidelines released by the Hellenic Centre for Con-
trol and Prevention of Infectious Diseases and the 
ATS/IDSA Guidelines treatment was considered ap-
propriate (depending on the severity of CAP and risk 
factors for pneumococcal resistance) for the patients 
requiring hospital admission when 1) monotherapy 
with a respiratory quinolone 2) anti-pneumococcal 
beta-lactam/macrolide combination or 3) a proper 
beta lactam/fluoroquinolone combination, were ad-
ministered2,27. Appropriateness was assessed only for 
patients without previous treatment.
Statistical Analysis
Data comparison between pulmonary and internal 
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medicine departments concerning CURB-65 scores 
and antibiotic treatment was performed by x2 test.
RESULTS
Curb-65 index
109 patients admitted to hospital due to CAP were 
identified. Six patients were excluded due to immu-
nosuppression and three patients due to incomplete 
data. Finally, 100 patients were included in the study. 
Patients’ demographics and pneumonia localization 
are shown it Table 1. CURB-65 score was 0 in 15 pa-
tients, 1 in 24, 2 in 37, 3 in 13, 4 in 10 and 5 in one, 
as presented in Table 2. No difference was detected 
in CURB-65 index distribution between patients hos-
pitalized in pulmonary and internal medicine depart-
ments (x2 = 3.739, p = 0.689, f = 5). 
Aggravating factors not included in CURB-65 
Parapneumonic effusion was evident in 4 patients 
with a CURB-65 score of 0, 2 patients with a score of 
1, 1 with a score of 2 and 2 with a score of 4. Arterial 
blood pH was assessed in 81 patients and respiratory 
acidosis was detected in 6. Hypoxemia was present in 
49 out of 84 patients (47 in pulmonary departments). 
Out of these patients, 6 had a CURB-65 score of 0 
(12.2%), 9 a score of 1 (18.4%), 17 of 2 (34.7%), 9 of 
3 (18.4%) and 8 a score of 4 (16.3%). Only 13 patients 
hospitalized for CAP with a CURB-65 index of 0-1 
had all of the following: sufficient oxygen saturation, 
no evidence of pleural effusion and no record of pre-
vious treatment for the same condition. Four of these 
patients had significant co morbidities and advanced 
age (>75 years).
Antimicrobial treatment
Twenty seven patients were already on antimicrobial 
therapy before admission whereas for the remaining 
73 patients treatment was initiated after admission. 
Out of the 27 patients already on treatment five were 
receiving a beta-lactam/macrolide combination, four 
a quinolone, eight a macrolide, five a beta-lactam, two 
an aminoglycoside and the remaining three were un-
der clindamycin, doxycycline or unknown medication 
(one case in each category). The regimen that was ad-
ministered to the patients during their hospitalization 
is shown in Table 3. No difference in the choice of 
treatment was detected between pulmonary and in-
ternal medicine departments (x2 = 6.353, p = 0.385, 
f = 6). In addition, 12 patients (8 in pulmonary and 4 
in internal medicine departments) received anti-influ-
enza treatment. 
Appropriateness of treatment
Fifty five (75,3%) out of the 73 previously untreated 
patients were administered appropriate treatment. 
More specifically 37 out of 48 patients in pulmonary 
and 18 out of 25 patients in internal medicine depart-
ments were given appropriate first-line treatment 
(x2 = 0.037, p = 0.848, f = 1). Out of the remaining 
18 patients (11 in pulmonary and 7 in internal medi-
cine departments), 17 were undertreated receiving 
antimicrobial agents that did not appropriately cover 
the spectrum of possible pathogens (11 received a 
beta-lactam, 3 received a macrolide, 2 ciprofloxacin/
clindamycin combination and 1 ciprofloxacin/macro-
lide combination). One patient was over-treated re-
ceiving a combination of beta-lactam, macrolide and 
doxycycline. Three patients died (with CURB-65 in-
dex 3, 4 and 5) and one was admitted in intensive care 
unit (ICU) and recovered (CURB-65 index 2).
DISCUSSION
The main findings of the present study are: 1) Almost 
40% of hospitalized patients with CAP in Greek hos-
pitals present at the Emergency Department with a 
CURB-65 score of 0-1, 2) 25% of patients hospital-
ized in common hospital wards due to CAP suffer in 
fact from severe CAP (CURB-65 ≥ 3) but are not ad-
mitted to ICU and 3) 25% of admitted to the hospital 
patients with CAP are undertreated in terms of appro-
priate coverage for common CAP pathogens.
The implementation of guidelines considering 
admission for CAP is overlooked quite often, since 
multiple studies had constantly demonstrate that low-
risk patients tend to be admitted in hospitals2,6,14-18,23. 
Hospitalization increases time to normal activity resti-
tution, risk of thromboembolic events and superinfec-
tion2. In addition, the substantial increase of health-
care cost is of particular concern, since inpatient care 
is 25 times more expensive than outpatient manage-
ment2,23,28. In that setting, unnecessary hospitalizations 
represent a significant financial burden to the national 
health systems. 
A possible explanation for the hospitalization of 
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low-risk patients may be that severity indexes are un-
der-utilized in routine clinical practice at EDs29. Our 
results are in agreement with those by Triantafyllidis 
et al23 who concluded that almost one out of two hos-
pitalized patients with CAP in Greek hospitals could 
have been treated as outpatients. 
However, it is undisputedly clear that the final de-
cision about hospital admission should take in account 
a variety of criteria not included into any proposed 
severity assessment rule, such as the mental and so-
cial status of the patients and availability of outpatient 
support2,14,29,30,31. In the case of Greece, the outpatient 
support services are underdeveloped, thus, the hospi-
tal-supervised follow-up of the acutely ill outpatients 
is uncertain. Moreover, the decision for admission is 
frequently dictated by the need for further investiga-
tion, failure of appropriate previous treatment, and 
the presence of additional severity markers such as 
hypoxemia or clinically substantial pleural effusion 
that are not included in CURB-6529,32. Indeed, in the 
present study oxygen treatment was necessary for 
58% of patients, the majority of whom were treated in 
departments of pulmonary medicine. Noteworthy, 15 
of these patients presented with a CURB-65 score of 
0-1. Although the present study was not designed to 
identify the reasons behind guideline non-adherence, 
our findings are in agreement with previous investi-
gations29,32 that consider failure of previous treatment, 
hypoxemia and pleural effusion as significant expla-
nations for the admission of low-risk patients. Indeed 
out of the 39 patients with a CURB-65 index of 0-1, 
only 13 did not present with at least one of the above 
factors. Out of these 13 patients, 4 were older than 
75 years and suffered from significant co-morbidities. 
For the remaining 9 patients (i.e 25% of patients with 
a CURB-65 of 0-1), no medical or social reason for 
admission could be identified. Similarly Choudhury 
et al in a large prospective trial concluded that ap-
proximately 20% of patients hospitalized due to CAP 
despite a low CUPR-65 index had no clear reason for 
admission29.
Despite the possible overtreatment of low-risk pa-
tients, 21 out of 24 patients with severe CAP (CURB-
65 ≥ 3) were successfully treated in hospital wards. 
The only patient who was transferred to the ICU and 
recovered presented with a CURB-65 score of 2. With 
the exception of those patients which satisfy the major 
IDSA/ATS criteria2 and require emergent transfer to 
the ICU, most Greek clinicians prefer to admit less 
critically ill patients in common wards, possibly due 
to the limited availability of ICU beds. Moreover it is 
generally accepted that most of the proposed severity 
scores have low discriminative performances in iden-
tifying patients requiring ICU admission6,33. In con-
cordance to this, Marrie et al have demonstrated that 
up to 14% of patients with a PSI of IV and V can be 
safely treated on an ambulatory basis34,35. 
Interestingly, empirical treatment was compliant 
with Greek National Guidelines in 75% of cases. This 
percentage, although far from perfect, corresponds to 
previously reported compliance36,37. In a recent report 
from Greece23 the observed compliance was report-
ed to lower (60%), however the exact treatment op-
tions that were considered as compliant to the relative 
guidelines were not specified. Although the impact of 
guideline adherence on mortality has been debated38,39, 
several studies have shown that guideline–compliant 
empirical treatment leads to reduced mortality19-22,37. 
Factors that are associated with adherence are special-
ty of the attending physician and the severity of pneu-
monia37,40. In the present study the impact of pneumo-
nia severity on adherence was not assessed due to the 
small sample size. Moreover, no significant difference 
in the selection of the antimicrobial regimen between 
pulmonary physicians and internal medicine special-
ists was observed. Despite the fact that non-adherence 
was not higher than expected it is clear that almost 
25% of hospitalized patients with CAP receive treat-
ment that does not adequately cover the common re-
spiratory pathogens and the possible resistance pat-
terns. The majority of these patients (11/18) did not 
receive treatment for “atypical” bacteria. Although 
this practice is not in accordance with international 
and Greek guidelines, a recent meta-analysis has not 
found any benefit of survival or clinical efficacy in 
hospitalized patients with CAP receiving additional 
empiric coverage of «atypical» pathogens, compared 
to those without such coverage41. It is therefore possi-
ble that this discordance with guidelines did not have 
any negative consequences on patients’ outcome. 
The present study is one of the few reports about 
CAP management in Greece. Limitations that should 
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be addressed are the low number of patients, the un-
availability of 30-day mortality and the fact that non-
hospitalized patients were not included. Despite these 
limitations our results are in accordance with previous 
Greek studies23,24 suggesting that there is still a neces-
sity for more efficient medical education, particularly 
in this field. Furthermore outpatient support and read-
ily access to public primary care facilities are critical 
aspects of CAP management in order to reduce unnec-
essary hospitalizations, especially in countries suffer-
ing from economic recession, like Greece.
In conclusion adherence of Greek physicians 
working in public hospitals to international and Greek 
guidelines concerning selection of patients with CAP 
who require hospitalization and empirical antibiotic 
treatment is rather poor and should be addressed. 
However concerning decision for admission, the non-
adherence may not be entirely wrong, since CURB-
65 index should not dictate need for hospitalization 
but rather be used as an adjunct to clinical judgment. 
The present study provides further evidence that only 
a proportion of patients with low CURB-5 index can 
actually be safely treated as outpatients. Identification 
of this group and enhancing outpatient support may 
effectively reduce the number of unnecessary hospi-






IDSA/ATS: Infectious Diseases Society of America 
and the American Thoracic Society 
PSI: Pneumonia Severity Index
ICU: intensive care unit
Table 1. Patients’ demographics and pneumonia localization.
Gender: men/women 62/38




chronic heart disease 41%
neurologic/psychiatric disease 21%
chronic obstructive pulmonary disease 17%
Pneumonia localization
right/left/bilateral (n = 94) 58/28/14
Table 2. Distribution of CURB-65 scores in patients hospitalized in Pulmonary and Internal Medicine departments. 
CURB- 65
score
Dpt of Pulmonary Medicine
(n, %)
Dpt of Internal Medicine
(n, %)
Τotal
0 11 (16.2) 4 (12.5) 15
1 16 (23.5) 8 (25) 24
2 23 (33.8) 14 (43.8) 37
3 8 (11.8) 5 (15.6) 13
4 9 (13.2) 1 (3.1) 10
5 1 (1.5) 0 1
Τotal 68 32 100
Dpt: Department. 
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ΠΕΡΙΛΗΨΗ: Σκοπός. Η τήρηση των οδηγιών για την πνευμονία της κοινότητας (ΠΚ) είναι μικρότερη από το επιθυμητό. 
Σκοπός της παρούσας μελέτης είναι η εκτίμηση της συμμόρφωσης των γιατρών στα Δημόσια Νοσοκομεία με τις Ελληνικές 
οδηγίες όσον αφορά αφενός τη χρήση του δείκτη CURB-65 για την επιλογή των ασθενών με ΠΚ που χρήζουν νοσηλείας 
και αφετέρου την εμπειρική αντιμικροβιακή θεραπεία.
Μέθοδοι. Πρόκειται για μία προοπτική πολυκεντρική μελέτη σε τέσσερεις πνευμονολογικές και παθολογικές κλινικές. Σε 
ασθενείς που νοσηλεύονταν λόγω ΠΚ καταγράφηκαν ο δείκτης CURB-65, το αντιβιοτικό σχήμα και οι επιβαρυντικοί πα-
ράγοντες (παραπνευμονική συλλογή, χαμηλή οξυγόνωση και προηγούμενη αντιμικροβιακή θεραπεία).
Αποτελέσματα. Από το σύνολο 100 ασθενών (μέση ηλικία ± sd: 69,41 ± 17,34 έτη), οι 39 εμφάνισαν χαμηλό (0-1), οι 37 μέσο 
(2) και οι 24 υψηλό (≥ 3) δείκτη CURB-65. Μόνο 25% των ασθενών με χαμηλό δείκτη CURB-65 δεν είχαν κανέναν από 
τους προαναφερθέντες επιβαρυντικούς παράγοντες. Το 75% των ασθενών χωρίς προηγηθείσα θεραπεία έλαβαν κατάλληλη 
αγωγή στο νοσοκομείο. 
Συμπεράσματα. Η συμμόρφωση των Ελλήνων γιατρών με τις οδηγίες για τη ΠΚ είναι μάλλον φτωχή. Παρά το υψηλό ποσοστό 
των νοσηλευομένων ασθενών με χαμηλό δείκτη CURB-65, η συνύπαρξη επιβαρυντικών παραγόντων συνηγορεί στο ότι ο 
δείκτης αυτός δεν θα πρέπει να αποτελεί το μοναδικό κριτήριο για τη νοσηλεία των ασθενών. Η αναγνώριση των ασθενών που 
μπορούν να αντιμετωπιστούν με ασφάλεια εξωνοσοκομειακά θα μπορούσε να ελαττώσει τον αριθμό των περιττών νοσηλειών. 
Λέξεις Κλειδιά: Πνευμονία της κοινότητας, Οδηγίες, Δείκτης CURB-65, Εμπειρική αντιμικροβιακή αγωγή.
Συμμόρφωση των Ελλήνων γιατρών στις οδηγίες για την αντιμετώπιση  
της πνευμονίας της κοινότητας.
Σεραφείμ Φουντάς, Κατερίνα Μανίκα, Μάρθα Λαδά, Αλίκη-Λήδα Τσαγκρίδη,  
Μαρία Κηπουρού, Ιωάννης Κιουμής
Μονάδα Αναπνευστικών Λοιμώξεων, Πνευμονολογική Κλινική ΑΠΘ, ΓΝΘ «Γ. Παπανικολάου», Θεσσαλονίκη, Ελλάδα
Table 3. Antibiotic treatment in patients hospitalized in Pulmonary and Internal Medicine departments. 
Antibiotic therapy Dpt of Pulmonary Medicine
(n, %)
Dpt of Internal Medicine
(n, %)
respiratory quinolone 20 (29.4) 10 (31.3)
beta-lactam/macrolide 27 (39.7) 13 (40.6)
macrolide 1 (1.5) 2 (6.2)
beta-Lactam 9 (13.2) 4 (12.5)
ciprofloxacin/clindamycin 3 (4.4) 0
beta-lactam/quinolone 5 (7.4) 0
other 3 (4.4) 3 (9.4)
Total 68 32
Dpt: Department. 
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